NASDAQ:TSVT 2seventy bio (TSVT) Stock Price, News & Analysis $4.98 -0.01 (-0.20%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About 2seventy bio Stock (NASDAQ:TSVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 2seventy bio alerts:Sign Up Key Stats Today's Range$4.86▼$5.0050-Day Range$4.18▼$5.0552-Week Range$1.53▼$6.40Volume192,303 shsAverage Volume806,360 shsMarket Capitalization$256.47 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingModerate Buy Company Overview2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Read More… [Urgent] Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. 2seventy bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks40th Percentile Overall ScoreTSVT MarketRank™: 2seventy bio scored higher than 40% of companies evaluated by MarketBeat, and ranked 757th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus Rating2seventy bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 4 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst Coverage2seventy bio has only been the subject of 1 research reports in the past 90 days.Read more about 2seventy bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 2seventy bio are expected to grow in the coming year, from ($1.23) to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 2seventy bio is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 2seventy bio is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio2seventy bio has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 2seventy bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.04% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in 2seventy bio has recently increased by 3.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield2seventy bio does not currently pay a dividend.Dividend Growth2seventy bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.04% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in 2seventy bio has recently increased by 3.70%, indicating that investor sentiment is decreasing. News and Social Media1.3 / 5News SentimentN/A News Sentiment2seventy bio has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for 2seventy bio this week, compared to 2 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 2seventy bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,817.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of 2seventy bio is held by insiders.Percentage Held by Institutions93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 2seventy bio's insider trading history. Receive TSVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TSVT Stock News HeadlinesSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVTOctober 17 at 7:29 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVTOctober 9, 2024 | prnewswire.com[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.October 17, 2024 | Paradigm Press (Ad)TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the FirmOctober 9, 2024 | globenewswire.comTSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the FirmOctober 7, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVTOctober 3, 2024 | prnewswire.comTSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the FirmSeptember 29, 2024 | prnewswire.comBuy Rating Affirmed for 2seventy bio Despite Trial Setback: Niche Market Strategy and Safety Profile Underpin Positive OutlookSeptember 28, 2024 | markets.businessinsider.comSee More Headlines TSVT Stock Analysis - Frequently Asked Questions How have TSVT shares performed this year? 2seventy bio's stock was trading at $4.27 at the beginning of 2024. Since then, TSVT shares have increased by 16.6% and is now trading at $4.98. View the best growth stocks for 2024 here. How were 2seventy bio's earnings last quarter? 2seventy bio, Inc. (NASDAQ:TSVT) released its earnings results on Wednesday, August, 7th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. The firm had revenue of $8.97 million for the quarter, compared to analysts' expectations of $11.43 million. 2seventy bio had a negative trailing twelve-month return on equity of 66.01% and a negative net margin of 354.16%. Who are 2seventy bio's major shareholders? 2seventy bio's top institutional investors include Exchange Traded Concepts LLC (0.07%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Kynam Capital Management, Lp, Casdin Capital, Llc, Nick Leschly, Victoria Eatwell, Philip D Gregory, William D Baird III, Jessica Snow and Nicola Heffron. View institutional ownership trends. How do I buy shares of 2seventy bio? Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of 2seventy bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that 2seventy bio investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Home Depot (HD), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/07/2024Today10/17/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSVT CUSIPN/A CIK1860782 Webwww.2seventybio.com Phone339-499-9300FaxN/AEmployees440Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$18.00 Low Stock Price Target$2.00 Potential Upside/Downside+80.7%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-217,570,000.00 Net Margins-354.16% Pretax Margin-354.16% Return on Equity-66.01% Return on Assets-29.65% Debt Debt-to-Equity RatioN/A Current Ratio4.76 Quick Ratio4.76 Sales & Book Value Annual Sales$100.39 million Price / Sales2.55 Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book0.99Miscellaneous Outstanding Shares51,500,000Free Float47,790,000Market Cap$256.47 million OptionableOptionable Beta1.77 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:TSVT) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.